Last reviewed · How we verify
Irinotecan, oxaliplatin, and cetuximab
Irinotecan, oxaliplatin, and cetuximab is a Small molecule drug developed by New Mexico Cancer Research Alliance. It is currently in Phase 2 development. Also known as: Eloxatin, ERBITUX.
At a glance
| Generic name | Irinotecan, oxaliplatin, and cetuximab |
|---|---|
| Also known as | Eloxatin, ERBITUX |
| Sponsor | New Mexico Cancer Research Alliance |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer (PHASE2)
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (PHASE1)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (PHASE1)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irinotecan, oxaliplatin, and cetuximab CI brief — competitive landscape report
- Irinotecan, oxaliplatin, and cetuximab updates RSS · CI watch RSS
- New Mexico Cancer Research Alliance portfolio CI
Frequently asked questions about Irinotecan, oxaliplatin, and cetuximab
What is Irinotecan, oxaliplatin, and cetuximab?
Irinotecan, oxaliplatin, and cetuximab is a Small molecule drug developed by New Mexico Cancer Research Alliance.
Who makes Irinotecan, oxaliplatin, and cetuximab?
Irinotecan, oxaliplatin, and cetuximab is developed by New Mexico Cancer Research Alliance (see full New Mexico Cancer Research Alliance pipeline at /company/new-mexico-cancer-research-alliance).
Is Irinotecan, oxaliplatin, and cetuximab also known as anything else?
Irinotecan, oxaliplatin, and cetuximab is also known as Eloxatin, ERBITUX.
What development phase is Irinotecan, oxaliplatin, and cetuximab in?
Irinotecan, oxaliplatin, and cetuximab is in Phase 2.
Related
- Manufacturer: New Mexico Cancer Research Alliance — full pipeline
- Also known as: Eloxatin, ERBITUX
- Compare: Irinotecan, oxaliplatin, and cetuximab vs similar drugs
- Pricing: Irinotecan, oxaliplatin, and cetuximab cost, discount & access